Biomarin Pharmaceutical (BMRN) FY2016 results: revenue $1.1 billion, up 25.5% on the year
Biomarin Pharmaceutical Inc. (BMRN) reported revenue of $1.1 billion for fiscal 2016, the year ended 31 December 2016, up 25.5% on the year before. Net income was -$630 million, and diluted earnings per share $-3.81. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2017.
Revenue
$1.1 billion
+25.5% on the year
FY2009FY2016
Operating margin
-71.9%
-12.4% a year earlier
FY2009FY2016
Net income
-$630 million
FY2009FY2016
Diluted EPS
-$3.81
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
1,117
890
749
+25.5%
Cost of revenue
210
152
122
+37.9%
Gross profit
907
738
627
+23.0%
Gross margin
81.2%
82.9%
83.7%
Research and development
662
635
462
+4.3%
Selling, general and administrative
477
402
302
+18.5%
Operating income
-803
-111
-92.9
Operating margin
-71.9%
-12.4%
-12.4%
Interest expense
39.5
38.2
36.6
+3.3%
Pre-tax income
-831
-155
-125
Income tax
-201
17.1
9.1
Net income
-630
-172
-134
Net margin
-56.4%
-19.3%
-17.9%
Diluted EPS
-$3.81
-$1.07
-$0.92
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
-228
-219
n/a
Capital expenditure
148
228
117
-34.8%
Free cash flow
-376
-447
n/a
Free cash flow margin
-33.7%
-50.2%
n/a
Cash from investing
-484
n/a
n/a
Cash from financing
727
n/a
n/a
Depreciation and amortisation
96.9
47.2
45.9
+105.4%
Share-based compensation
135
112
86.4
+20.7%
Diluted shares, weighted
166m
160m
146m
+3.9%
Shares outstanding at period end
173m
162m
149m
+6.9%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
2,766
2,401
1,528
+15.2%
Debt
683
662
643
+3.2%
Other liabilities
574
666
305
-13.8%
Total liabilities and equity
4,024
3,729
2,475
+7.9%
Fixed assets
799
704
524
+13.4%
Goodwill
197
197
54.3
0.0%
Intangible assets
554
684
157
-19.0%
Investments
954
621
168
+53.6%
Cash and equivalents
408
397
875
+2.8%
Receivables
215
165
144
+30.5%
Inventory
355
272
199
+30.7%
Other assets
541
689
354
-21.5%
Total assets
4,024
3,729
2,475
+7.9%
10-K for the year ended 31 December 2016, filed 27 February 2017: the filing.